Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
NCT04075266Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2020
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Roche. Started Jan 2020; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04075266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075266.